Average trade mark-up on these drugs now around 170%, reaching 700% in some cases; intervention to cut prices by up to 70% of MRP, resulting in cumulative annual savings of ₹2,500 crore for patients
Average trade mark-up on these drugs now around 170%, reaching 700% in some cases; intervention to cut prices by up to 70% of MRP, resulting in cumulative annual savings of ₹2,500 crore for patients
Average trade mark-up on these drugs now around 170%, reaching 700% in some cases; intervention to cut prices by up to 70% of MRP, resulting in cumulative annual savings of ₹2,500 crore for patients
Average trade mark-up on these drugs now around 170%, reaching 700% in some cases; intervention to cut prices by up to 70% of MRP, resulting in cumulative annual savings of ₹2,500 crore for patients
Average trade mark-up on these drugs now around 170%, reaching 700% in some cases; intervention to cut prices by up to 70% of MRP, resulting in cumulative annual savings of ₹2,500 crore for patients
Move could cut MRPs by up to 70%, save patients ₹2,500 crore annually; comes amid SC scrutiny of high mark-ups
<iframe src="https://hindustansphere.com/embed/cluster/ca0cb134171f5ec4799b79115bc154197b35bdda" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Centre to cap trade margins on non-scheduled cancer drugs to 30% of MRP"></iframe>
